Emergent BioSolutions Announces Executive Management Team of New Spin-Off Company Aptevo Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced the anticipated executive management team of Aptevo Therapeutics Inc., Emergent’s planned Biosciences business spin-off company. Members of the...
Emergent BioSolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth Plan
2015 Preliminary Estimates: Total revenues of $520 to $525 million, a 16% increase over 2014 (at midpoint) GAAP net income of $60 to $64 million, a 69% increase over 2014 (at midpoint) Adjusted net...
Emergent BioSolutions Receives Favorable IRS Private Letter Ruling in Connection With its Planned Biosciences Business Spin-Off
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a favorable private letter ruling from the Internal Revenue Service related to the planned spin-off of its biosciences...
Emergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced the anticipated composition of the board of directors of Aptevo Therapeutics Inc., which is the name of Emergent’s biosciences business...
FDA Approves Emergent BioSolutions’ BioThrax for Post-Exposure Prophylaxis
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) approved its supplemental Biologics License Application to expand the label of BioThrax®...
Emergent BioSolutions to Participate in First Quarter 2016 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of...
Emergent BioSolutions Reports Third Quarter and Nine Months 2015 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30,...
Emergent BioSolutions to Release Third Quarter 2015 Financial Results and Conduct a Conference Call on November 5, 2015
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, November 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2015, recent...
Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune...
Emergent BioSolutions Reports Second Quarter and Six Months 2015 Financial Results and Reaffirms 2015 Guidance
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30,...
Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded Company
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized management to pursue a tax-free spin-off of the company's Biosciences business into a separate,...
Emergent BioSolutions Expands Biodefense Business Through Launch of a Military-Grade Auto-Injector Device for Chemical Threats
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it is launching a ruggedized, military-grade auto-injector device, known as Emergard™, which is designed for intramuscular self-injection...